Australia's most trusted
source of pharma news
Thursday, 05 June 2025
Posted 3 June 2024 AM
Half of Opthea's Board of Directors have resigned following a devastating Phase 3 trial miss and a slashing of the workforce.
On Monday the company announced in a corporate update that four directors have "decided to step down from the Board to streamline the governance of the organisation".
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.